Generic name: Clobenzorex.
Pharmaceutical form and formulation: Each capsule contains: Clobenzorex hydrochloride 30 mg. Excipient cbp 1capsule.
Therapeutic indications: Chlorobenzorex is an anorectic, it is indicated as: Auxiliary in the treatment of exogenous obesity, Treatment adjuvant to the diet in patients with obesity and a body mass index (BMI) equal to or greater than 30 kg / m 2 (patients who have not responded to the diet).
Contraindications: It is contraindicated in patients with a history of: Vascular diseases: Pulmonary arterial hypertension. Uncontrolled systemic arterial hypertension. Current or previous medical history of cardiovascular or cerebral vascular disease. Advanced studies of arteriosclerosis. Neurological and Psychiatric Diseases: Current or previous medical history of psychiatric disorders including anorexia nervosa and depression. Use of antidepressants or monoamine oxidase inhibitors (MAOIs). Clobenzorex should not be administered within 14 days of taking MAOIs as hypertensive crisis may occur. Propensity to drug use or known alcoholism. States of psychomotor agitation. Endocrine diseases like:Hyperthyroidism Others: Known hypersensitivity or idiosyncrasy to sympathomimetic amines. Angle-closure glaucoma. Risk of urinary retention linked to urethro-prostatic disorders. The use of Clobenzorex with other centrally acting anorectics (association therapy) is contraindicated due to the increased risk of development of pulmonary arterial hypertension with life-threatening consequences. Children under 12 years old. Pregnancy and lactation.
General precautions:Cases of severe (often fatal) pulmonary arterial hypertension have been reported during treatment with Clobenzorex-type anorectics. An epidemiological study has shown that taking anorectics is a risk factor involved in the development of pulmonary arterial hypertension and that the use of anorectics is strongly associated with an increased risk of said adverse reaction. Given this rare but serious risk, the following points should be considered: Treatment will always be carried out under the supervision of a physician experienced in the treatment of obesity. Before prescribing Clobenzorex, secondary organic causes of obesity should be excluded. The indication and duration of treatment will be scrupulously respected.2 and when the duration of the treatment is greater than three months. The occurrence or worsening of exertional dyspnea suggests the possibility of pulmonary arterial hypertension. In these circumstances, treatment should be discontinued immediately and the patient should undergo clinical evaluation following the instructions of their treating physician. Considerations to take into account:Sympathomimetic amines lose anorectic power after several weeks of treatment. Prolonged treatment can cause a phenomenon of pharmacological tolerance and drug dependence. Prolonged use of Clobenzorex may induce dependence with withdrawal syndrome by stopping treatment. If tolerance develops, treatment should be discontinued. Severe psychotic disorders can occur in patients with predisposition, although it is not very frequent, it should be taken into account. The recommended dose should not be exceeded as this does not condition a better therapeutic response. Cardiovascular disease and CVD have often been reported rarely related to rapid weight loss. In obese patients at risk of disease, special care must be taken to ensure gradual and controlled weight loss. Clobenzorex will not be prescribed to patients with a current or previous history of cardiovascular disease or CVD. Only when the benefits outweigh the risks, Clobenzorex can be used with caution in epileptic patients. Treatment must be carried out through a comprehensive program that will include dietary, medical and psychotherapeutic measures.